epilepsy. Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
Conditions
Interventions
Intervention 1: Adding Verapamil tab as 120 mg daily to previous anti epileptic drugs in patients with refractory temporal lobe epilepsy for 2 months and then comparing the changes in seizure frequenc
Treatment - Drugs
Adding Verapamil tab as 120 mg daily to previous anti epileptic drugs in patients with refractory temporal lobe epilepsy for 2 months and then comparing the changes in seizure frequency and quality to
Adding Verapamil tab as 240 mg daily to previous anti epileptic drugs in patients with refractory temporal lobe epilepsy for 2 months and then comparing the changes in seizure frequency and quality to
Sponsors
Shiraz University of Medical Science
Eligibility
Sex/Gender
All
Age
18 Years to 53 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: - Male/female patients, aged 18 and above. - Diagnosis of epilepsy made on the basis of clinical and EEG findings. - Refractory epilepsy is defined as failure of two or more AEDs at maximal tolerated doses and 2 or more seizures per month. - There have been no more than 4 weeks between seizures over the 2 months prior to entry to the study. - Having stable medication regimen for 8 weeks prior to entry. - Patient is male or a non-pregnant female adequately protected from conception. - Informed consent by patients or their families/care givers. Exclusion criteria: - Patient has a progressive neurological condition. - Patient has a history of non-compliance for seizure diary completion or frequent clinic visits. - Patient is pregnant at the time of enrolment. - Patient has any serious medical illness or major psychiatric disorder, history of psudoseizure, or history of suicidal attempt in the past 5 years. - Patient has any contraindication for verapamil administration including: severe GI narrowing, heart failure, hypertrophic cardiomyopathy, cardiac conduction disturbances, hypotension, hepatic impairment, renal impairment, and known history of hypersensitivity to verapamil.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seizure frequency. Timepoint: monthly. Method of measurement: questionnaire and check list.;Seizure quality. Timepoint: monthly. Method of measurement: questionnaire and check list. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure. Timepoint: one week after starting Verapamil, one week after titrating Verapamil, and then monthly. Method of measurement: Digital blood pressure monitor.;Pulse rate. Timepoint: one week after starting Verapamil, one week after titrating Verapamil, and then monthly. Method of measurement: counting manually. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed mohammad ali razavizadegan jahromi
Shiraz University of Medical Science
Outcome results
None listed